STOCKHOLM, April 29, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in hepatocellular carcinoma (HCC) has been accepted for presentation at the European Society for Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress in June 26-29, 2024 in Munich.
STOCKHOLM, Sept. 7, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical needs, today announces that data on the company's leading program fostroxacitabine bralpamide (fostrox) and its potential effect on hepatocellular carcinoma (HCC), will be presented at the International Liver Cancer Association (ILCA) Annual Meeting, September 7-9 in Amsterdam.
STOCKHOLM, Sept. 4, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today promising interim safety and efficacy data from its ongoing phase 1b/2a study of first-in-class candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC) patients for whom current first- or second-line treatment has proven ineffective or is not tolerable.
STOCKHOLM, Aug. 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the 15th patient with advanced hepatocellular carcinoma (HCC) has been included in the ongoing phase 2a study. The study evaluates safety and efficacy with the candidate drug fostrox in combination with Lenvima® in patients for whom current first- or second-line treatment has proven ineffective or is not tolerable.
The Chinese patent authority has granted approval for Medivir’s patent application for fostroxacitabine bralpamide (Fostrox).
STOCKHOLM, March 17, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that data from the company's leading program fostroxacitabine bralpamide (fostrox) and its potential effect on hepatocellular carcinoma (HCC), will be presented at the American Association for Cancer Research (AACR) Annual Meeting, on April 14-19, in Orlando, USA.
STOCKHOLM, March 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the first patient with hepatocellular carcinoma (HCC) has started treatment in phase 2a with the candidate drug fostroxacitabine bralpamide (fostrox) in combination with Lenvima®.